Blood-stage infection of P.vivax
Phase 2Biologic
Blood-stage infection of P.vivax is one of 71 biologic programs targeting Liver Cancer. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
70
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
61 competitors in Liver Cancer
#DrugCompanyPhaseTrials
1Idamycin
PfizerApproved
Blenoxane
Bristol-Myers SquibbApproved
Opdivo
Bristol-Myers SquibbPhase 3
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Eloxatin
TevaPhase 3
Lenvima
EisaiPhase 3
Rapamune
PPrism Pharmaceuticals
Approved
Glucophage
EMD SeronoApproved
Alimta
SShawn Eagle
Approved
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- CCAS Lamvac Biotech Co., Ltd.